Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ABBV is in the long-term up 243% in 9 years.
Description: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||4||EPS Growth - 4 Quarters||-44.47%||EPS Growth - Q/Q||-115.9%|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||2.31%||Sales Growth - Q/Q||-7.56%||P/E||17.76|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||6.8%||ROE||131.88%||ROI||11.6%|
|Current Ratio||1.39||Quick Ratio||1.3||Long Term Debt/Equity||2.45||Debt Ratio||8.02|
|Gross Margin||79.12%||Operating Margin||18.33%||Net Profit Margin||8.89%||Dividend Payout Ratio||-154.52%|
|Cash From Financing Activities||-930 M||Cash From Investing Activities||-873 M||Cash From Operating Activities||1.59 B||Gross Profit||4.58 B|
|Net Profit||1.37 B||Operating Profit||2.11 B||Total Assets||26.7 B||Total Current Assets||15.41 B|
|Total Current Liabilities||11.05 B||Total Debt||15.27 B||Total Liabilities||25.32 B||Total Revenue||5.48 B|
|High 52 week||121.94||Low 52 week||64.52||Last close||99.98||Last change||0.75%|
|RSI||36.24||Average true range||2.28||Beta||1.14||Volume||4.37 M|
|Simple moving average 20 days||-2.68%||Simple moving average 50 days||2.42%||Simple moving average 200 days||2.97%|
|Performance Week||-2.94%||Performance Month||0.35%||Performance Quart||-11.94%||Performance Half||6.85%|
|Performance Year||50.73%||Performance Year-to-date||5.21%||Volatility daily||1.66%||Volatility weekly||3.7%|
|Volatility monthly||7.59%||Volatility yearly||26.29%||Relative Volume||229.33%||Average Volume||8.94 M|
|New High||New Low|
2019-06-25 23:17:00 | Replay: What to Watch in The Markets: AbbVie-Allergan, Micron, Buffett, and More
2019-06-25 18:05:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Allergan Plc
2019-06-25 17:33:24 | US Stock Market Overview – Stocks Drop on US/Iran Conflict
2019-06-25 17:33:00 | Surging Allergan Stock Is Approaching AbbVie’s Bid Price
2019-06-25 17:12:00 | The Dow Fell Because the Trump-Xi Meeting May Cover More Than Just Trade
2019-06-25 17:02:00 | What Happened in the Stock Market Today
2019-06-25 16:21:00 | Dow Ends Lower, Stocks Fall as Powell Says Fed 'Grappling' with Rate Cut
2019-06-25 16:15:08 | AbbVie + Allergan: Where Are The Synergies?
2019-06-25 16:10:43 | Pharma Buying Spree Continues As AbbVie Takes Out Allergan For $63 Billion
2019-06-25 16:05:22 | Abbvie Drops by a Record as Allergan Deal Fails to End Doubts
2019-06-25 15:01:07 | AbbVie ABBV Stock Falls After $63 Billion Allergan Acquisition Announcement
2019-06-25 14:58:17 | Allergan Options Bull Wins Big on AbbVie Buyout Buzz
2019-06-25 14:05:00 | AbbVie Shareholders Will Get No Vote on Purchase of Allergan
2019-06-25 13:58:06 | Allergan Finance, LLC -- Moody's reviews Allergan's Baa3 ratings for upgrade
2019-06-25 12:38:00 | Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition
2019-06-25 12:37:51 | AbbVie Buys Allergan for Over $60 Billion
2019-06-25 12:28:00 | Stock Market News: AbbVie Bets Big; Can Microsoft Stay on Top?
2019-06-25 12:23:00 | AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere
2019-06-25 12:12:28 | Will David Tepper Be Happy about the AbbVie-Allergan Deal?
2019-06-25 12:10:38 | AbbVie’s $63 Billion Mega Deal Returns Focus to Debt-Fueled M&A
2019-06-24 17:45:09 | AbbVie ABBV Dips More Than Broader Markets: What You Should Know
2019-06-24 09:17:00 | FDA lifts hold on one of AbbVie's trials of venetoclax
2019-06-24 08:42:12 | Forget Bargain Hunting: Tap 5 Stocks With Rising P/E
2019-06-21 17:36:09 | Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval
2019-06-21 11:21:03 | Top Ranked Income Stocks to Buy for June 21st
2019-06-21 10:30:02 | Sanofi/Regeneron's Asthma Candidate Meets Goal in Study
2019-06-20 13:45:00 | AbbVie Declares Quarterly Dividend
2019-06-20 09:10:01 | Is AbbVie ABBV a Great Value Stock Right Now?
2019-06-20 07:30:45 | These New Product Launches Could Partially Offset Humira’s Losses
2019-06-19 16:20:02 | What to Look for in AbbVie’s Oncology Portfolio in 2019
2019-06-19 14:50:02 | How Is AbbVie Positioned in June?
2019-06-19 13:19:57 | AbbVie or Allergan: Which Is a Better Pick in June?
2019-06-19 08:00:00 | Is Abbott Laboratories a Buy?
2019-06-19 07:34:09 | How Do Rate Cuts Impact Healthcare Stocks?
2019-06-17 18:13:10 | Bayer to Invest 5 Billion Euros in Weedkiller Research
2019-06-17 17:45:09 | AbbVie ABBV Stock Sinks As Market Gains: What You Should Know
2019-06-17 17:26:09 | J&J's JNJ Tremfya Meets Goal in Psoriatic Arthritis Study
2019-06-17 15:41:07 | Novartis NVS Announces Promising Data on Tasigna & Hyrimoz
2019-06-17 10:25:02 | Top Ranked Income Stocks to Buy for June 17th
2019-06-17 09:15:01 | Why AbbVie ABBV is a Top Dividend Stock for Your Portfolio
2019-06-17 06:00:00 | Why AbbVie Is a Retiree's Dream Stock
2019-06-14 12:06:04 | 3 Big Pharma Stocks to Buy Right Now
2019-06-13 08:24:12 | Pfizer's PFE Xeljanz Effective As Monotherapy in RA Study
2019-06-12 08:15:00 | 5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
2019-06-11 15:15:22 | 10 Smart Dividend Stocks for the Rest of the Year
2019-06-11 09:54:01 | Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
2019-06-11 09:03:01 | Lilly Announces Tradjenta Cardiovascular Outcome Study Data